Cargando…

Comparative proteomics of a model MCF10A-KRas(G12V) cell line reveals a distinct molecular signature of the KRas(G12V) cell surface

Oncogenic Ras mutants play a major role in the etiology of most aggressive and deadly carcinomas in humans. In spite of continuous efforts, effective pharmacological treatments targeting oncogenic Ras isoforms have not been developed. Cell-surface proteins represent top therapeutic targets primarily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xiaoying, Chan, King C., Waters, Andrew M., Bess, Matthew, Harned, Adam, Wei, Bih-Rong, Loncarek, Jadranka, Luke, Brian T., Orsburn, Benjamin C., Hollinger, Bradley D., Stephens, Robert M., Bagni, Rachel, Martinko, Alex, Wells, James A., Nissley, Dwight V., McCormick, Frank, Whiteley, Gordon, Blonder, Josip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341332/ https://www.ncbi.nlm.nih.gov/pubmed/27894102 http://dx.doi.org/10.18632/oncotarget.13566

Ejemplares similares

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context
por: Monticone, Massimiliano, et al.
Publicado: (2008)

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023)

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS(G12D) Inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023)

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
por: Wright, Katharine M., et al.
Publicado: (2023)

Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
por: Ye, Xiaoying, et al.
Publicado: (2018)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras(G12V) mice
por: Kumar, Gaurav, et al.
Publicado: (2021)

An integrated method for single cell proteomics with simultaneous measurements of intracellular drug concentration implicates new mechanisms for adaptation to KRAS(G12D) inhibitors
por: Orsburn, Benjamin C.
Publicado: (2023)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients
por: Fu, Xin-Hui, et al.
Publicado: (2019)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
por: Ohnami, Shumpei, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Reduced dynamic complexity allows structure elucidation of an excited state of KRAS(G13D)
por: Chao, Fa-An, et al.
Publicado: (2023)

Reduced HRAS(G12V)-Driven Tumorigenesis of Cell Lines Expressing KRAS(C118S)
por: Huang, Lu, et al.
Publicado: (2015)

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
por: Lu, Dan, et al.
Publicado: (2023)

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
por: Miyamoto-Sato, Etsuko, et al.
Publicado: (2023)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility
por: Chen, Chih-Chieh, et al.
Publicado: (2020)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma
por: Mohamed, Abdalla D., et al.
Publicado: (2018)

The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer
por: Hung, Pei-Shan, et al.
Publicado: (2020)

Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v02jf5tln3r3h3n7870brp5abp